Skip to main content

Sempra Energy

(SRE) - Get DBA Sempra Report

is in a great position right now because we are heading into the hurricane season, and that means we are probably going to see higher natural gas prices, Aaron Task told a caller on Cramer's

"RealMoney" radio show Friday.

Task, co-executive editor of

, will be filling in for Cramer this week.

Task advised the caller to put a stop in at $44 (the stock was recently at $45.46).

Although alternative energy plays are legitimate, they are more speculative long-term plays, he said. Right now, natural gas, oil, and other traditional energy makes up the bulk of the resources we need, and Task believes Sempra is well-positioned to benefit from that.


( PALM) quarterly statement did disappoint, Task told a caller. However, the company's guidance for the full fiscal 2007 year was above expectations so some people may think of it as a buying opportunity when taking a long-term view, he said.

Task's guest, Cody Willard, president of CL Willard Capital and a contributor to

, said he likes Palm from a long-term perspective. It is cheap and he believes it will earn a lot of money in the next three or four years.

Although the stock is getting hit hard off bad guidance, Willard said he wouldn't chase it, but nor would he be selling it with a longer-term view.

Akamai Technologies

Scroll to Continue

TheStreet Recommends

(AKAM) - Get Akamai Technologies Inc. Report

has tripled in 12 months, Willard said, adding that he likes the company and believes it is well-positioned, but expensive.

When a caller inquired about

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

Task said that after buying



(PFE) - Get Pfizer Inc. Report

consumer products line, the stock got hit because there was concern that they overpaid for those assets

Johnson & Johnson paid $16.5 billion, which is four times the revenue that the consumer products division was earning for Pfizer, Task said.

However, he believes it was a great move for Johnson & Johnson as the consumer products segment is a faster-growing business than the pharmaceutical business. Task said he sees the fallen stock as a buying opportunity and believes down the road this acquisition will be looked upon as a savvy move.

There has been a lot of opportunity in big-cap, stable, blue-chip stocks like

Home Depot

(HD) - Get Home Depot Inc. (The) Report

, Task told a caller.

However, the problem with Home Depot is that the Fed's tightening has put downward pressure on the real estate market and not as many people are buying homes, he said. Home Depot is suffering from that.

Task suggested the caller to look into big-cap retailer


(WMT) - Get Walmart Inc. Report

, which he said is a stock that has a chance to turn around here.

To see the most recent edition of The RealMoney Radio Recap in its entirety, please click here. This recap is published every day around 3 p.m. ET.

Aaron L. Task is the co-executive editor of In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships.

Click here

to send him an email.